David Roh
Columbia University, NY·Medicine & Clinical Research·Early-career
Bleeding into the brain, called intracranial or intracerebral hemorrhage, is the deadliest form of stroke, and there are few treatments that reliably improve how patients recover. Two problems drive the damage: the bleed can keep growing in the first hours, and the injured brain may not receive enough oxygen afterward.
- Fields
Medicine & Clinical Research
Physiology
Neuroscience
- Topics
intracerebral hemorrhage
intracranial hemorrhage
hemorrhagic stroke
- Grants
- 3 known grants, through Apr 2030
What they work on
- Separate the clotting role of red blood cells from their oxygen-delivery role after brain hemorrhage, using mouse models of anemia, hemorrhage and red cell transfusion together with a prospective patient study measuring clotting function and brain oxygenation.
- Test whether viscoelastic hemostatic assays, bedside tests that track whole-blood clot formation over time, detect clotting impairments that predict hematoma expansion in patients whose standard plasma tests appear normal.
- Identify specific clotting proteins driving bleed growth through proteomic analysis of patient blood, compared against standard tests of prothrombin time, platelet count and fibrinogen.
- Determine whether clotting defects relevant to continued bleeding differ among common hemorrhage subgroups, pairing laboratory results with neuroimaging measures of bleed growth and neurological outcome assessments.
- Link red blood cell product and donor characteristics from the REDS-IV-P multicenter transfusion network to hospital data from brain hemorrhage patients to find which transfusion features predict effective oxygen delivery and recovery.
More about the research
Work in this lab sits at the meeting point of blood-clotting science, transfusion medicine and neurocritical care, asking which blood-based factors actually determine whether bleeding continues and whether brain tissue stays oxygenated. The shared goal across projects is to replace one-size-fits-all transfusion and clotting treatments with approaches matched to individual patients.
Why it matters
Brain hemorrhage carries the highest death and disability rate of any stroke type, and current blanket treatments to stop bleeding have not improved outcomes and sometimes caused harm. Identifying which clotting defects actually precede continued bleeding, and which blood products work best for these patients, could yield bedside tests and tailored transfusion strategies that prevent bleed growth while sparing patients from unnecessary transfusions and their risks.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
FunctIonal coaGulation and HemosTasis after IntraCerebral Hemorrhage (FIGHT-ICH)
NIH · Jul 2025 – Apr 2030
RBc transfusion Characteristics in IntraCranial Hemorrhage (RBC-ICH)
NIH · Aug 2026 – Jul 2028
Erythrocyte contribution to coagulopathy and cerebral oxygenation after intracerebral hemorrhage
NIH · Sep 2021 – Aug 2026
Closest labs
Krystalyn Hudson
University of Virginia, VA·Microbiology & Immunology
Test whether red blood cell units rich in reticulocytes, young red cells that still contain mitochondria, raise alloantibody rates after transfusion, using mouse models that mimic repeat blood donation.
Yohei Hisada
University of North Carolina at Chapel Hill, NC·Medicine & Clinical Research
Test whether podoplanin on leukemia blast cells drives platelet loss in acute promyelocytic leukemia by activating platelets through their CLEC-2 receptor, using xenograft and allograft mouse models that reproduce patient clotting abnormalities.
Melanie Fields
Washington University in St Louis, MO·Medicine & Clinical Research
Compare cerebral metabolic stress and oxygen metabolism, measured by brain MRI, between females aged 12–21 with iron deficiency anemia and matched non-anemic females.
The school
Columbia University: 89 labs on PI Pages, $1.4B a year on research, 625 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.